Allergan 4th-qtr revenues up 6%; earnings exceed expectations

31 October 2012

US health care firm Allergan (NYSE: AGN) revealed yesterday that revenues for its fiscal fourth-quarter ended September 30, 2012, rose 6% to $1.41 billion, undershooting analysts’ estimates of $1.43 billion.

Allergan reported $0.82 diluted earnings per share attributable to stockholders compared to $0.81 for the third quarter of 2011. Non-GAAP diluted earnings per share were $1.06, a 15.2% increase, compared with the expectations of 25 analysts polled by Thomson Reuters of $1.04, also beating forecasts for two consecutive quarters,

For the full year of 2012, Allergan expects non-GAAP EPS of $4.17-$4.19, on total product net sales between $5.695 billion and $5.77 billion. Analysts project earnings of $4.17 on $5.82 billion revenue for the year

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical